|Podcasts|August 23, 2018

Episode 16: Specialty Pharma

Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like. Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.

Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 

 


Related to this article

Pharmaceutical executive daily
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.